Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 1, 2011, Pages 164-167

  Weinberg, Linda R ^a   Albom, Mark S ^a   Angeles, Thelma S ^a   Husten, Jean ^a   Lisko, Joseph G ^a   McHugh, Robert J ^a   Milkiewicz, Karen L ^a   Murthy, Seetha ^a   Ott, Gregory R ^a   Theroff, Jay P ^a   Tripathy, Rabindranath ^a   Underiner, Ted L ^a   Zificsak, Craig A ^a   Dorsey, Bruce D ^a  

^a CEPHALON INC   (United States)

Author keywords

c Met; Diaminopyrimidine; Kinase inhibitors; Mesenchymal epithelial transition factor

Indexed keywords

2 AMINO N METHYLBENZMIDE; 2 ARYLAMINOPYRIMIDINE; 2,4 DIAMINOPYRIMIDINE DERIVATIVE; BENZAMIDE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL INTERACTION; DRUG SELECTIVITY; ENZYME ACTIVITY; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BICYCLO COMPOUNDS; CELL LINE, TUMOR; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650513746     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.045     Document Type: Article

References (10)

1. J.J. Cui Expert Opin. Ther. Patents 17 2007 1035
2. B. Peruzzi, and D.P. Bottaro Clin. Cancer Res. 12 2006 3657
3. T.L. Underiner, T. Herbertz, and S.J. Miknyoczki Anti-Cancer Agents Med. Chem. 10 2010 7
4. I. Dussault, and S. Bellon Anti-Cancer Agents Med. Chem. 9 2009 221
5. G.R. Ott, R. Tripathy, M. Cheng, R. McHugh, A.V. Anzalone, T.L. Underiner, M.A. Curry, M.R. Quail, L. Lu, W. Wan, T.S. Angeles, M.S. Albom, L.D. Aimone, M.A. Ator, B.A. Ruggeri, and B.D. Dorsey ACS Med. Chem. Lett. 2010 10.1021/ml100158s
6. Zificsak, C. A.; Theroff, J. P.; Aimone, L. D.; Albom, M. S.; Angeles, T. S.; Brown, R.; Galinis, D.; Grobelny, J. V.; Herbertz, T.; Husten, J.; Kocsis, L. S.; LoSardo, C.; Miknyoczki, S. J.; Murthy, S.; Rolon-Steele, D.; Underiner, T. L.; Worrell, C. S.; Zeigler, K.; Dorsey, B. D. Bioorg. Med. Chem. Lett., submitted for publication.
7. Ahmed, G.; Bohnstedt, A.; Breslin, H. J.; Burke, J.; Curry, M. A.; Diebold, J. L.; Dorsey, B.; Dugan, B. J.; Feng, D.; Gingrich, D. E.; Guo, T.; Ho, K.; Learn, K. S.; Lisko, J. G.; Liu, R.; Mesaros, E. F.; Milkiewicz, K.; Ott, G. R.; Parrish, J.; Theroff, J. P.; Thieu, T. V.; Tripathy, R.; Underiner, T. L.; Wagner, J. C.; Weinberg, L.; Wells, G. J.; You, M.; Zificsak, C. A. International Patent WO 2008051547A1, 2008.
8. P.A.S. Smith, and W.L. Berry J. Org. Chem. 26 1961 27
9. As a key regulator of glucose metabolism, selectivity for c-Met over IR was preferred to be >10-fold in enzyme assays.
10. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, M.G. Benedetti, T.A. Carter, P. Ciceri, P.T. Edeen, M. Floyd, J.M. Ford, M. Galvin, J.L. Gerlach, R.M. Grotzfeld, S. Herrgard, D.E. Insko, M.A. Insko, A.G. Lai, J. Lelias, S.A. Mehta, Z.V. Milanov, A.M. Velasco, L.M. Wodicka, H.K. Patel, P.P. Zarrinkar, and D.J. Lockhart Nat. Biotechnol. 23 2005 329